Pricing Log in Create free account

InterCure Ltd. (INCR) vs Zhengye Biotechnology Holding Limited (ZYBT)

InterCure Ltd. and Zhengye Biotechnology Holding Limited are both Drug Manufacturers Specialty & Generic companies. InterCure Ltd. and Zhengye Biotechnology Holding Limited are of similar size ($41.0M and $39.1M). Across the 5 metrics below, InterCure Ltd. leads on 3 and Zhengye Biotechnology Holding Limited on 2.

Valuation

Metric INCR ZYBT Drug Manufacturers Specialty & Generic median
P/E 6.23 — 20.55
P/S 0.24 — 2.08
P/B 0.23 n/m 1.79
Price to free cash flow n/m n/m 16.29
EV/EBITDA 6.17 n/m 12.22
EV/Sales 0.56 n/m 2.87
Earnings yield 16.05% — (15.94%)
Free cash flow yield (2.85%) 0.00% 0.00%

Profitability

Metric INCR ZYBT Drug Manufacturers Specialty & Generic median
Gross margin 32.74% — 53.51%
Operating margin 0.00% — 0.00%
Net margin 4.88% — (2.45%)
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% 0.00% (0.80%)
Return on assets 0.00% 0.00% (1.67%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric INCR ZYBT Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 16.15% — 5.22%
EPS growth (last fiscal year) 52.50% (800.00%) 42.91%
Revenue growth, 5-year CAGR 31.11% — 7.24%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric INCR ZYBT Drug Manufacturers Specialty & Generic median
Debt to equity 0.27 0.24 0.04
Current ratio 1.85 1.14 2.41
Net debt to EBITDA (4.07) (0.51) 1.01

Dividend

Metric INCR ZYBT Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.45%
Payout ratio — — 0.27

Size

Metric INCR ZYBT Drug Manufacturers Specialty & Generic median
Market cap 39.05m 41.02m 315.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack